LHC Group, Inc.

▲ Bull Case

• ◆JV-model moat was real, durable, and acquisition-magnetic: The hospital JV structure made LHCG referral-defensible at the local-market level and uniquely attractive to a payer seeking vertical integration—UHG's $170 bid (a ~2–3x EBITDA-turn premium to AMED-style independent operators) directly quantified this advantage.
• ◆Trough earnings mispriced the asset by ~$30–40/share: Q1 2022 trading at $120–130 was anchored to GAAP EPS of $1.30 (depressed by travel-nurse premium and deal costs); normalized adjusted EPS of ~$5.00 supported intrinsic value of $150–$170 even on standalone DCF, demonstrating a classic trough-earnings mispricing opportunity.
• ◆Demographic and policy tailwinds remained intact: 10,000 Americans turning 65 daily through 2030+, CMS preference for home-based vs. institutional care, and Medicare Advantage growth all supported a 4–6% organic growth path into FY2027, sufficient to support base-case margin recovery.

▼ Bear Case

• ◆CMS PDGM behavioral adjustment threatened structural revenue step-down: The FY2023 proposed -7.85% rate cut (if implemented in full without mitigation) would have created ~$50–60M annual EBITDA headwind; cumulative cuts could have stacked to 15–22% terminal revenue impact in a worst case.
• ◆Labor cost normalization may have proven stickier than modeled: FY2022 travel-nurse spike (peaking ~14–18% of clinical payroll vs. 3–4% pre-COVID) was treated as cyclical, but structural nursing shortages (BLS projected 195K annual RN demand vs. constrained supply through 2031) could have kept margins at 8–10% rather than the 17.9% terminal base case.
• ◆Medicare Advantage growth created persistent per-episode pricing erosion: MA growth from 35% (2019) to 48% (2022) to projected 60%+ (2025) of Medicare beneficiaries created a structural reimbursement-mix headwind of ~10–15% per MA episode vs. FFS, only partially offset by LHCG's nascent VBC contract strategy.

“The pre-deal Street debate was not about LHCG's quality but about earnings timing and valuation framework. The bear camp anchored to GAAP EPS and forward consensus of ~$3.50, saw 20x trough EBITDA as full, and held targets at $120–140. The bull camp focused on strategic-buyer optionality and normalized $300M+ EBITDA, pointing to UHG/Humana/CVS payer-integration moves as inevitable acquirers, with targets at $160–180. The deal resolved the debate by validating the bull camp on direction and the strategic-buyer thesis on magnitude, with the $170 price landing at the midpoint of fair value estimates.”

• ◆March 29, 2022 — UHG announcement of $170/share all-cash acquisition; realized catalyst with +30% single-day move
• ◆August–October 2022 — FTC second-request review resolved cleanly without divestitures or conditions
• ◆January 12, 2023 — Shareholder vote (99%+ approval) and deal close finalized at $170/share
• ◆Ongoing: HHVBP nationwide expansion (favorable for large-quality operators)
• ◆Ongoing: CMS PDGM behavioral adjustment resolution (annual rule cycle; critical for industry margins)
• ◆Ongoing: Continued payer/provider M&A wave (CVS/Aetna, Humana, Cigna) as vertical integration thesis evolves

• ◆CMS PDGM rate cuts (Critical severity): Proposed -7.85% behavioral cut would create $50–60M annual EBITDA headwind; cumulative cuts compound to 15–22% revenue impact in worst case
• ◆Labor shortage and travel nurse premium persistence (High severity): FY2022 spike peaking ~14–18% of clinical payroll vs. 3–4% pre-COVID; structural RN shortages (BLS 195K annual demand vs. constrained supply through 2031) could keep margins compressed longer than modeled
• ◆Medicare Advantage mix shift and pricing erosion (Medium severity): MA growth to 60%+ of Medicare beneficiaries by 2025 creates persistent ~10–15% per-episode reimbursement headwind vs. FFS; only partially offset by VBC strategy
• ◆Regulatory and compliance risks (Medium severity): PEPPER audits, FCA investigations, CON challenges; LHCG had clean record but risks remain industry-wide
• ◆Goodwill impairment risk (Medium severity): Large goodwill base from Almost Family and HCA-Brookdale acquisitions; structural margin pressure could trigger impairments >$200M